Colchicine—regeneration of an old drug

Immunomodulation by colchicine is a well-established therapy for targeting inflammatory pathways in gout, pericarditis and Behchet’s disease. In more recent times, evidence has emerged demonstrating a potential role for colchicine in several cardiac conditions. This article aims to summarise the evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Casey, Aoife, Quinn, Sandra, McAdam, Brendan, Kennedy, Mark, Sheahan, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886190/
https://www.ncbi.nlm.nih.gov/pubmed/35230596
http://dx.doi.org/10.1007/s11845-022-02938-7
_version_ 1784660607608291328
author Casey, Aoife
Quinn, Sandra
McAdam, Brendan
Kennedy, Mark
Sheahan, Richard
author_facet Casey, Aoife
Quinn, Sandra
McAdam, Brendan
Kennedy, Mark
Sheahan, Richard
author_sort Casey, Aoife
collection PubMed
description Immunomodulation by colchicine is a well-established therapy for targeting inflammatory pathways in gout, pericarditis and Behchet’s disease. In more recent times, evidence has emerged demonstrating a potential role for colchicine in several cardiac conditions. This article aims to summarise the evidence behind the established guidelines for use of low-dose colchicine in pericarditis and examine the evolving evidence for its use in cardiovascular disease and most recently COVID-19.
format Online
Article
Text
id pubmed-8886190
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88861902022-03-01 Colchicine—regeneration of an old drug Casey, Aoife Quinn, Sandra McAdam, Brendan Kennedy, Mark Sheahan, Richard Ir J Med Sci Review Article Immunomodulation by colchicine is a well-established therapy for targeting inflammatory pathways in gout, pericarditis and Behchet’s disease. In more recent times, evidence has emerged demonstrating a potential role for colchicine in several cardiac conditions. This article aims to summarise the evidence behind the established guidelines for use of low-dose colchicine in pericarditis and examine the evolving evidence for its use in cardiovascular disease and most recently COVID-19. Springer International Publishing 2022-03-01 2023 /pmc/articles/PMC8886190/ /pubmed/35230596 http://dx.doi.org/10.1007/s11845-022-02938-7 Text en © The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Casey, Aoife
Quinn, Sandra
McAdam, Brendan
Kennedy, Mark
Sheahan, Richard
Colchicine—regeneration of an old drug
title Colchicine—regeneration of an old drug
title_full Colchicine—regeneration of an old drug
title_fullStr Colchicine—regeneration of an old drug
title_full_unstemmed Colchicine—regeneration of an old drug
title_short Colchicine—regeneration of an old drug
title_sort colchicine—regeneration of an old drug
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886190/
https://www.ncbi.nlm.nih.gov/pubmed/35230596
http://dx.doi.org/10.1007/s11845-022-02938-7
work_keys_str_mv AT caseyaoife colchicineregenerationofanolddrug
AT quinnsandra colchicineregenerationofanolddrug
AT mcadambrendan colchicineregenerationofanolddrug
AT kennedymark colchicineregenerationofanolddrug
AT sheahanrichard colchicineregenerationofanolddrug

Ejemplares similares